1. Introduction {#s0005}
===============

Air pollution is a significant environmental risk factor for lung cancer. For every increase of 5 μg/m^3^ of particulate matter (PM) smaller than 2.5 μm in diameter (PM~2.5~) in the environment, the risk of lung cancer rises by 18%; for every elevation of 10 μg/m^3^ in PM smaller than 10 μm (PM~10~), the risk increases by 22% ([@bb0130]). Anthropogenic PM~2.5~ is associated with 220,000 lung cancer mortalities annually ([@bb0005]). Based on sufficient evidence of carcinogenicity, the International Agency for Research on Cancer (IARC) Working Group recently classified outdoor air pollution and related PM as Group 1 carcinogenic to humans ([@bb0095]). However, the carcinogenic mechanism of air pollution remains to be dissected using systematic approaches.

Xuanwei (XW) City in Yunnan Province of China (Fig. S1), provides an example of the epidemiological association between PM~10~, PM~2.5~ and lung cancer ([@bb0175], [@bb0020], [@bb0110]). This city and the neighboring Fuyuan (FY) county have a large deposit of smoky coal ([@bb0110]). Until the 1970s, residents of these regions used smoky coal in unvented indoor fire pits for domestic cooking and heating, all processes that release high concentrations of PM~10~ and PM~2.5~. These airborne particles contain high concentrations of polycyclic aromatic hydrocarbons (PAHs) including benzo(a)pyrene (BaP) and polar compounds that are highly mutagenic ([@bb0110]). Lung cancer incidence in XW is among the highest in China ([@bb0110], [@bb0175]), and a reduction in lung cancer morbidity was noted in the 1990s after stove improvement in central XW, supporting the association between air pollution and lung cancer ([@bb0080]). The findings in XW had been cited in the IARC monograph classifying indoor emissions from household combustion of coal as "carcinogenic to humans (Group 1)" ([@bb0170]). However, the overall lung cancer incidence in this region has been increasing ([@bb0175], [@bb0025]), possibly due to pollutants generated by coal-burning industrial plants that moved into the area ([@bb0020]). In 2011, a survey ([@bb0090]) of 52,833 residents living in 382 rural villages in XW/FY reported 363 subjects diagnosed with lung cancer, with the world age-standardized rate (ASR) of 426/100,000 in some regions of XW. Population in these highly polluted regions (HPR) lends a unique opportunity to dissect the carcinogenesis that is specifically related to air pollution, and we took this opportunity by sequencing the whole genomes of lung cancers from these regions to provide a comprehensive landscape of genomic alterations in this study.

2. Materials and Methods {#s0010}
========================

2.1. Study Design {#s0015}
-----------------

We sequenced the whole genomes of 14 non-small-cell lung cancers (NSCLCs) from HPR, and performed targeted exome sequencing of 2010 genes in additional 150 primary NSCLCs from HPR and control regions (CR) in the rest of Yunnan and Guangdong Province where the level of air pollution and lung cancer incidence was comparable to most parts of China ([@bb0160], [@bb0025]). The mutation patterns of HPR and CR NSCLCs were compared, and the exposure--response relationship was analyzed (Fig. S1).

2.2. Patients {#s0020}
-------------

The study was approved by the Local Research Ethics Committees of all participating sites. Tumor and adjacent normal lung tissues and peripheral blood samples were obtained from 164 patients with previously untreated NSCLCs ([Tables 1](#t0005){ref-type="table"}, [S1](#ec0005){ref-type="supplementary-material"}, [Figs. 1](#f0005){ref-type="fig"} and S2). The diagnosis and TNM stage were established as previously described ([@bb0015], [@bb0045]). The patients resided in their communities and rarely (or never) stayed in other regions for a long time, and had regular life routines and regular daily time-spent indoors and outdoors. The exposure dosages of the patients to BaP were estimated by historical measurements in various regions of China that used different fuels and their smoking histories ([@bb0140], [@bb0150]). The most recent 10 years were excluded to allow for a hypothesized 10-year latency period between exposure and clinical recognition of lung cancer. Whole-genome sequencing (WGS) was performed in 14 HPR patients ([Table S1](#ec0005){ref-type="supplementary-material"} and Figures S), and exome sequencing was conducted in additional 65 HPR and 85 CR patients ([Table S1](#ec0005){ref-type="supplementary-material"}).

2.3. Analytic Platforms {#s0025}
-----------------------

DNAs and RNAs were isolated from cancer or counterpart normal tissues, sequencing libraries were constructed, and sequenced using the Illumina Hiseq2000 platform. A SNP array using Illumina High Density Genome Wide Human 660WQuad_v1 was performed to detect somatic copy number alterations (SCNAs) throughout the genomes. Mutations of 2010 genes identified by WGS were screened in 150 additional NSCLCs by exome captured and sequencing. The protocols are detailed in eMethods.

3. Results {#s0030}
==========

3.1. Somatic Mutation Profile in HPR NSCLCs {#s0035}
-------------------------------------------

For whole genome sequencing (WGS), cancer DNAs were sequenced to an average of 65.74 × (range, 61.02 ×--74.64 ×) and normal controls of 43.16 × (30.07 ×--78.70 ×) coverage. Point mutations, indels, somatic structural variations, and somatic copy number alterations (SCNAs) were found throughout the 14 NSCLC genomes (Fig. S3, [Fig. 1](#f0005){ref-type="fig"} and [Table S1](#ec0005){ref-type="supplementary-material"}, [Table S2](#ec0010){ref-type="supplementary-material"}, [Table S3](#ec0015){ref-type="supplementary-material"}). We reported a mean of 12.75 somatic genomic mutations/Mb, 8.16 exonic mutations/Mb, and 289 exonic mutations/tumor ([Table S1](#ec0005){ref-type="supplementary-material"}). Only an average of 0.74% mutations was found in coding sequences (CDS) (Fig. S4A, B). Using capillary sequencing, 331/361 (91.7%) mutations in CDS were validated. Smoker, non-smokers, squamous cell carcinoma (SCC) and adenocarcinoma (AD) patients had approximately equal mutations in their genomes and CDS (Fig. S4C). The numbers of non-synonymous mutations, synonymous mutations ([Fig. 1](#f0005){ref-type="fig"}A), chromosomal rearrangements ([Table S2](#ec0010){ref-type="supplementary-material"}) and somatic gene rearrangements ([Fig. 1](#f0005){ref-type="fig"}B) were not associated with smoking status or age. Within predicted promoter regions, there is a positive correlation between GC content and somatic mutation rate (Fig. S4D).

We analyzed the CDS mutations and reported a mean of 158 non-recurring and 31 recurring (defined as mutated in at least 2 samples) mutated genes per tumor ([Fig. 1](#f0005){ref-type="fig"}C and [Table S4](#ec0020){ref-type="supplementary-material"}). Three genes, *MUC16*, *RYR2* and *TP53*, were mutated in 7 (50%) of the 14 patients. *CSMD3*, *RYR1*, *TTN* and *ZNF831* were mutated in 5 (35.7%) of the patients. There were 18 (including *XIRP2* and *ANK2*), 65 (including *EGFR* and *KRAS*), 338 (including *CACNA1E*, *CACNA1S*, *CACNA2D1* and *RYR3*) and 2209 genes mutated in 4 (28.57%), 3 (21.43%), 2 (14.29%), and 1 (7.14%) of the 14 patients, respectively ([Table S4](#ec0020){ref-type="supplementary-material"}). Among the 428 recurrently mutated genes, 381 ones had a ratio of non-synonymous to synonymous mutations (d~N~/d~S~) \> 2. These genes fall into 18 categories ([Table S4](#ec0020){ref-type="supplementary-material"} and [Fig. 1](#f0005){ref-type="fig"}D), with calcium signaling and ion channel-related genes ([Fig. 1](#f0005){ref-type="fig"}E), structural proteins, and transcription factors as the three most frequently mutated gene categories.

3.2. Somatic Copy Number Alterations (SCNAs) {#s0040}
--------------------------------------------

A total of 479 SCNA segments and a mean of 34 copy number variations (CNVs) per tumor were detected ([Table S3](#ec0015){ref-type="supplementary-material"} and Fig. S5A). We identified 5 regions of significant CNVs: copy loss in 13q12.3-q34 (containing 13 genes including *BRCA2*, *ERCC5*, and *RB1*), 4p16.1-p13 (containing 6 genes), 4q22.1-q35.2 (containing 18 genes including *CASP3*, *EGF*, and *FGF2*), and 3p24.3-12.2 (containing 17 genes including *TGFBR2* and *SETD2*); copy gain in 1q21.1-q44 (containing 35 genes including *ABL2*, *IL6R*, and *MCL1*) ([Table S3](#ec0015){ref-type="supplementary-material"}).

Some genes including *CYP1A1*, *CYP1B1*, *CAT*, and *ERCC1*, affect PAH metabolism, detoxification, PAH-DNA adduct formation and repair ([@bb0070]). We assessed 23 genes involved in these processes, and reported that 20 ones had copy loss in 12/14 patients, and 1 gene (*EPHX1*) had copy gain in 4/14 patients at the DNA level (Fig. S5B). By quantitative real-time RT-PCR analysis of 17 of these genes, we found that 13 genes were down-regulated in at least 7 patients, with down-regulated *CYP3A4* seen in 14 patients, decreased *CAT*, *CYP1A1*, and *NAT* in 13 patients, and down-regulated *GSTM1* in 12 cases (Fig. S5C). CNV was also frequently seen in DNA repair genes in the patients, with a mean of 114 copy loss and 17 copy gain genes per tumor ([Table S3](#ec0015){ref-type="supplementary-material"}).

3.3. Genomic Rearrangements {#s0045}
---------------------------

We used the CREST method ([@bb0165]) to detect and map the breakpoints of the somatic rearrangements among the 14 HPR patients. Totally, 992 chromosomal rearrangements including 573 (57.8%) gene rearrangements and 419 (42.2%) purely intergenic events were identified, with a mean of 71 genomic rearrangements per tumor ([Table S2](#ec0010){ref-type="supplementary-material"} and [Fig. 1](#f0005){ref-type="fig"}B). We identified six previously unreported interchromosomal in-frame fusion transcripts: *ARHGEF10*-*IMMP2L*, *COL13A1*-*DLD*, *PCDH15*-*SOX5*, *CACNA1B*-*FAF1*, *MCF2L2*-*PHF3*, and *ABCC8*-*C3orf55* in 5 patients (Fig. S6, A-F), and five previously unreported intrachromosomal in-frame-fusion transcripts (*PLCB1*-*CRLS1*, *DOCK2-TENM2*, *SOX5-ST8SIA1*, *TADA2B-TBC1D19* and *NINJ2-NTF3*) in four patients (Fig. S7, A-F). Sanger sequencing of PCR products using genomic DNA of the samples was conducted, and 99/108 (91.7%) tested structural variations were validated.

3.4. Genomic Signatures {#s0050}
-----------------------

In 12/14 (85.7%) HPR patients, the C:G → A:T transversions were the most frequent nucleotide substitutions (Fig. S8A). The percentage of transversions ranged from 17.7% to 58.8% (Table S5; p = 0.008). In males, the percentage of A:T → G:C mutations were much higher than in females (Table S5; p = 0.008); in 2 of the 6 males, the most prevalent mutation was A:T → T:A (Fig. S8A). The most frequently observed dinucleotide change was GG → TT/CC → AA (p \< 0.001) (Fig. S8B). Among the trinucleotide alterations, XpCpG → XpApG was detected in 13/14 patients. CpCpX → CpApX and XpCpG → XpTpG were also detected (Fig. S8C).

3.5. Mutations in Calcium Signaling Genes {#s0055}
-----------------------------------------

Gene Ontology Analysis showed that motor activity, calcium ion binding, extracellular matrix structural constituent, ion binding, cation binding, and metal ion binding activity were affected (Table S6). Pathway analysis using single-nucleotide variation and indel data revealed that the differentially altered genes were significantly enriched in 46 KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways, including pathways involved in focal adhesion, calcium signaling and pathogenesis of NSCLC (p \< 0.0001) (Table S6). Indeed, some of the most frequently mutated genes ([Table S4](#ec0020){ref-type="supplementary-material"}) were related to calcium signaling, e.g., *RYR1-3*, which encode RYRs calcium release channels located on the membrane of the endoplasmic reticulum ([@bb0085]); *ANK2*, which is required for cardiac sinoatrial node Ca^2 +^ homeostasis; *XIRP2*, which is a target of the calcium-dependent transcription factor MEF2A; *CACNA1E* (or Cav~2.3~) ([@bb0145]), *CACNA1S* and *CACNA2D1*, which encode plasma membrane calcium channel subunits ([@bb0125]).

3.6. HPR NSCLCs Have Much More Mutations Than CR Patients {#s0060}
---------------------------------------------------------

To unveil the difference in somatic mutations between HPR and CR NSCLCs ([Table 1](#t0005){ref-type="table"}), exons of 2010 of the 2637 (76.2%) mutated genes found in WGS were captured and sequenced ([Table S7](#ec0025){ref-type="supplementary-material"}), and the results were confirmed by sequencing of PCR products using according primers (Table S8). Cancer DNAs were sequenced to an average of 140 × (54.8 ×--261 ×) and normal controls of 145.2 × (46.6 ×--218.5 ×) coverage. We found that the 79 HPR and 85 CR NSCLCs had a mean of 68 and 22 mutated genes per tumor ([Table 2](#t0010){ref-type="table"}), respectively (p \< 0.0001). The HPR NSCLCs had much more mutations, e.g., the total number of mutated genes ([Fig. 2](#f0010){ref-type="fig"}A), recurrent mutated genes ([Fig. 2](#f0010){ref-type="fig"}B), and genes mutated in more than 3%--10% tumor samples ([Fig. 2](#f0010){ref-type="fig"}C, [Table 2](#t0010){ref-type="table"}), than the CR patients. In HPR, the number of genes mutated in \> 3% samples was 785, more than 3 times higher than that in CR (213 genes; [Table 2](#t0010){ref-type="table"}). There were 59 genes which were mutated in \> 10% tumor samples in HPR NSCLCs, but only 5 genes (*TP53*, *EGFR*, *KRAS*, *COL22A1*, *PAPPA2*) were mutated in \> 10% tumor samples in CR ([Fig. 2](#f0010){ref-type="fig"}D). Among the 1529 recurrent mutated genes ([Table S7](#ec0025){ref-type="supplementary-material"}), 167 genes (including *TP53*, *RYR2*, *KRAS*, *CACNA1E*, *XIRP2*) had statistically significantly higher mutation rates in HPR than CR patients, but no gene had significantly higher mutation rate in CR than HPR patients. One gene, *TMEM132C*, was mutated in 7.59% HPR and 14.12% CR samples, respectively (p = 0.182; [Fig. 3](#f0015){ref-type="fig"}C).

3.7. Comparison of Somatic Mutations in HPR and CR NSCLCs {#s0065}
---------------------------------------------------------

We compared the mutation patterns in HPR and CR NSCLCs. Among the total 80 mutations (46 mutations in HPR and 34 ones in CR NSCLCs) of *TP53*, 9 common mutations (G154V, R158L, A159P, E171\*, Y220C, G244C, G245C, G245V, and E285K) were seen in both regions ([Fig. 3](#f0015){ref-type="fig"}A). However, most of the *TP53* mutations in HPR were different from those in CR cases. HPR NSCLCs had equal *EGFR* mutation rate to CR cases (p = 0.135). However, CR non-smokers had higher *EGFR* mutation rate (40%) than smokers (16.3%; p = 0.0158), while in HPR non-smokers (43.9%) had equal mutation rate to smokers (31.6%; p = 0.26). In HPR, 14/43 (32.6%) mutations occurred in G719, while in CR only 1/25 (4%) alterations was observed in this amino acid; 9 (20.9%) mutations occurred in S768 in HPR cases, but no mutation was seen in this site in CR NSCLCs ([Fig. 3](#f0015){ref-type="fig"}A). Mutations in *RYR2*, *COL22A1*, *PAPPA2* and *TMEM132C* in HPR NSCLCs were distinct to those found in CR patients ([Fig. 3](#f0015){ref-type="fig"}). Interestingly, 16/19 (84.2%) *KRAS* mutations in HPR NSCLCs and 10/11 (90.9%) KRAS mutations in CR patients were found in G12 ([Fig. 3](#f0015){ref-type="fig"}A), suggesting that NSCLCs of the two regions also had a few similar points in mutation patterns.

3.8. Association Between BaP Exposure and Gene Mutation {#s0070}
-------------------------------------------------------

Lifetime exposure to BaP was calculated by applying air concentration (ng/m^3^) reported for various regions of China that used different fuels for cooking and heating ([@bb0140]), an average inhalation rate of 20 m^3^/day, and the duration of exposure. Smoking a pack of filtered cigarettes per day was assigned a BaP exposure of 0.4 μg/day ([@bb0150]). The median value of BaP exposure in the HPR was 151.0 mg, five times as high as in the CR (30.1 mg) ([Fig. 4](#f0020){ref-type="fig"}A). By logistic regression, we found that the mutation frequencies of 70 genes (including *RYR2*, *MYH3*, *GPR144*, *RBCC1*, *NRXN2*, *KLHL1*, *TCHH*, *ARAP1*, *COL13A1*, *CUX2*, *ZNF800*, *KCNT1*, *XIRP2*, *CACNA1E* and *TP53*) were associated with BaP exposure (p \< 0.05; Table S9, [Fig. 4](#f0020){ref-type="fig"}B and Fig. S9).

4. Discussion {#s0075}
=============

In this study, we examined the cancer genomes of HPR NSCLCs to identify the genomic mutation profile associated with prolonged exposure to smoky coal pollutants. Of the 14 WGS patients, there was a mean of 12.75 somatic genomic mutations/Mb, 8.16 exonic mutations/Mb, and 289 exonic mutations/tumor. Among the 2010 genes sequenced by targeted exome sequencing, the HPR patients had 68 mutated genes/tumor, 3 times higher than that in CR cases. Previous studies demonstrated that smoker NSCLCs bear more somatic mutations than never-smokers ([@bb0065], [@bb0050]). However, in HPR, the smokers and non-smokers harbored equal numbers of mutations and gene rearrangements in their genome. In CR, stages III--IV cancers had more mutations in 6 genes (*KRAS*, *MYH13*, *TNR*, *ADAMTS20*, *PXDNL* and *SEZ6L*) than stages I--II tumors, while patients ≥ 65 years harbored more mutations in 4 genes (*RYR2*, *COL22A1*, *ADAMTS12* and *ZFPM2*) than patients \< 65 years; in HPR, only *ACVR2A* had more mutations in stages III--IV cancers than stages I--II tumors, and *ADCY7* had a higher mutation rate in patients ≥ 65 years than those \< 65 years ([Table S7](#ec0025){ref-type="supplementary-material"} sheet 4). These results demonstrate the genotoxic effect of air pollution and the urgent need to attenuate pollution.

PAHs are important carcinogens in PM~2.5~ and PM~10~ ([@bb0185], [@bb0110]). A variety of enzymes metabolize PAHs to more polar and water-soluble metabolites to be excreted from the body. However, during the course of metabolism, some unstable and reactive intermediates are formed, which can bind to DNA to form bulky DNA adducts ([@bb0055], [@bb0035]). At the same time, the cells constantly deal with the formation of DNA adducts by DNA repair processes to eliminate these alterations so that mutation does not occur ([@bb0070]). We showed that in the WGS NSCLCs, genes responsible for PAH detoxification (*GSTM1*, *GSTP1*, *GSTT1*) were mainly copy loss (Fig. S5B) or down-regulated (Fig. S5C), while genes involved in PAH activation (*CYP1B1* in particular; Fig. S5C) were mainly up-regulated. DNA repair genes were mainly copy loss or mutated ([Table S3](#ec0015){ref-type="supplementary-material"}). Mutations in DNA repair pathways have also been implicated in the production of chromosomal translocations ([@bb0010]). Therefore, the events in PAH metabolism and DNA repair genes may pave the way to genomic mutations and chromosomal translocations, and may represent an essential step to allow accumulation of significant mutations to initiate malignant transformation.

PAHs are associated with the C:G → A:T transversions in nucleotides ([@bb0135], [@bb0040]), and recent studies in cell lines showed that BaP can induce this type of nucleotide substitutions ([@bb0120]). We found that the C:G → A:T substitutions were the most frequent nucleotide substitutions in 12/14 patients (Fig. S8), and exome sequencing confirmed the prevalent of C:G → A:T transversions in HPR NSCLCs ([Table 2](#t0010){ref-type="table"}), indicating that PAHs were the main carcinogens for these patients. However, in 2/14 cases the most frequent nucleotide changes were A:T → T:A transitions (Fig. S8), suggesting that there might be other pollutants that caused this signature in the genomes.

Some genes, e.g., *TP53*, *EGFR*, and *KRAS*, have high frequency of mutations in lung cancer ([@bb0155], [@bb0065]), and ethnic and sex-related differences in mutation spectrum are noted ([@bb0030], [@bb0075]). We showed that the mutation pattern of *TP53*, *EGFR*, and *KRAS* in CR NSCLCs ([Figs. 2](#f0010){ref-type="fig"}D and [3](#f0015){ref-type="fig"}) was in consistence with previous report in Asian patients ([@bb0030]), and HPR patients also had high mutation rates in these genes ([Fig. 2](#f0010){ref-type="fig"}D). Some genes, e.g., *COL22A1*, *PAPPA2*, *TNR*, *TMEM132C*, *ADAMTS20*, *BAI3*, *CPS1*, and *OTOA*, had high mutation frequencies in both regions ([Table S7](#ec0025){ref-type="supplementary-material"}). Mutations in most genes, e.g., *TP53*, *COL22A1*, *PAPP2A*, *CACNA1E*, *MYH3*, *NRXN2*, *RYR2*, *XIRP2*, and *TMEM132C*, distributed throughout the entire genes were either missense or nonsense in nature; on the contrary, some genes, e.g., *EGFR* and *KRAS*, had mutation hot spots ([Fig. 3](#f0015){ref-type="fig"}). The results indicated that although NSCLCs from HPR and CR had distinct mutation patterns in many genes, they did show some similar points in some somatic mutations.

Alterations in Ca^2 +^ TRP, ORAI1 and RYR channels have been identified in cancer ([@bb0105], [@bb0060], [@bb0100]), and overexpression of *CACNA1E* are correlated with relapse in Wilms\' tumors ([@bb0115]), while *CACNA2D1* plays a role in maintaining the properties of tumor-initiating cells in hepatocellular carcinoma ([@bb0180]). Interestingly, [@bb0120] found that treatment of cells with BaP for 6 days leads to mutations in *CACNA1C* and *CACNA1G*. We showed that in the 79 HPR NSCLCs, calcium signaling-related genes *RYR2*, *RYR1*, *XIRP2*, *CACNA1E* and *ANK2* had high frequency mutations (29.1%--17.7%), compared to 1.2%--8.2% mutation rates in CR patients. In HPR NSCLCs, *RYR1* and *RYR2* had mutations of loss of function patterns, because the mutations were distributed throughout the entire genes and were either missense or nonsense in nature. *CACNA1B-FAF1* fusion (Fig. S6D) could also damage CACNA1B\'s Ca^2 +^ channel function, because its C-terminal ion transmission and calcium channel domains were deleted. The 23 *CACNA1E* mutations in 15/79 (19%) HPR lung cancers were missense mutations and distributed throughout the entire gene. Among them, 10/23 (43.5%) mutations were found in the amino acid 119--546 region, and 10/15 (67%) patients had one mutation in ion transmission, PKD channel or calcium channel domains ([Fig. 3](#f0015){ref-type="fig"}B). These mutations may interfere with the function of the calcium channel and the intracellular Ca^2 +^ concentration, the essential second messenger that can regulate nearly every aspect of cellular functions. Further investigation should be conducted to characterize the "driver mutation" aspects of these genes.

The following are the supplementary data related to this article.Supplementary materials.Table S1Clinical characteristics of tumors used in whole genome sequencing and summary of sequencing results of each tumor DNA.Table S2Chromosomal rearrangements in the whole genome sequencing patients.Table S3Somatic copy number alterations in the patients.Table S4The mutated genes found in whole genome sequencing.Table S7Mutations in 2010 genes in 164 non-small cell lung cancers.
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![Mutation landscape of lung cancer from HPR. (A): A stacked bar graph representing the total number of non-synonymous versus synonymous mutations in each patient. (B): Summary of somatic genic rearrangements in each patient. "Other Genic" indicates rearrangements linking an intergenic region to the 3′ portions of a genic footprint. (C): Total numbers of recurring and non-recurring mutations in each patient. (D): The 381 recurring mutated genes (with dN/dS \> 2), classified into 18 categories. (E): Mutations and copy number variations in calcium signal and ion channel genes.](gr1){#f0005}

![Comparison of mutations in HPR lung cancer with those in CR NSCLCs. (A): HPR NSCLCs bore more mutated genes than CR patients. (B): Comparison of recurrent mutated genes in HPR with those in CR NSCLCs. (C): Genes mutated in \> 5% tumor samples from HPR and CR. (D): Mutations in 59 genes whose mutation frequencies are \> 10% of HPR NSCLCs. Tumors are arranged from left to right in the top track.](gr2){#f0010}

![Mutations in some representative genes. Schematic representations of proteins encoded by the genes are shown. Numbers refer to amino acid residues. Mutations found in HPR and CR patients are shown in red and black, respectively. Each "+" corresponds to an independent, mutated tumor sample, and "\*" indicates a nonsense (truncating) mutation. Mutations underlined with a same-colored line are found in the same patient. (A): The five genes which were mutated in \> 10% tumor samples in both regions. (B): Representative five genes whose mutation rates in HPR lung cancer were significantly higher than in CR NSCLCs. (C): Mutations in TMEM132C which were mutated in 6/79 (7.59%) HPR NSCLCs and 12/85 (14.12%) CR lung cancers (p = 0.182).](gr3){#f0015}

![Association between mutations and exposure to BaP. (A): Estimated doses of the patients\' exposure to BaP. Sources of combustion of smoky coal and cigarette smoke were included. (B): Exposure--response relationship between BaP exposure and the mutation probability of 24 representative genes. See also Figure S9.](gr4){#f0020}

###### 

The demographic characteristics of the 164 NSCLC patients from HPR or CR.

  Characteristics           Total (n = 164)   HPR (n = 79)    CR (n = 85)
  ------------------------- ----------------- --------------- ---------------
  *Gender*                                                    
  Male                      101               42              59
  Female                    61                37              24
  n.d.                      2                 0               2
                                                              
  *Age*                                                       
  \< 65                     122               61              61
  ≥ 65                      40                18              22
  n.d.                      2                 0               2
  Median, range             56 \[34, 78\]     57 \[36, 76\]   59 \[34, 78\]
                                                              
  *Residence*                                                 
  Xuanwei/Fuyuan            79                79              0
  Rest of Yunnan            24                0               24
  Guangdong                 61                0               61
                                                              
  *Smoking*                                                   
  Smoker                    81                38              43
  Non-smoker                81                41              40
  n.d.                      2                 0               2
                                                              
  *Histology*                                                 
  Adenocarcinoma            112               64              48
  Squamous-cell carcinoma   46                14              32
  Adenosquamous carcinoma   0                 0               0
  Large-cell carcinoma      6                 0               0
                                                              
  *TNM stage*                                                 
  IA                        18                12              6
  IB                        47                25              22
  IIA                       13                2               11
  IIB                       22                9               13
  IIIA                      28                13              15
  IIIB                      15                9               6
  IV                        16                9               7
  n.d.                      5                 0               5

n.d.: not determined.

###### 

Comparison of mutations in the 2010 genes in HPR and CR NSCLCs.

                                   HPR (n = 79)   CR (n = 85)[⁎](#tf0005){ref-type="table-fn"}   p (HPR vs CR)                                                  
  -------------------------------- -------------- ---------------------------------------------- --------------- ------- -------- -------- -------- ----------- -----------
  Mutation/Mb (mean)               15.90          18.31                                          13.66           0.818   6.34     7.98     4.49     0.0297      3.611E-06
  G:C → T:A substitution           54.79%         54.03%                                         55.73%          0.114   41.92%   45.26%   38.08%   3.421E-05   1.711E-39
  Mutated genes/tumor              67.99          74.87                                          61.61           0.930   22.06    28.16    15.58    0.017       9.966E-07
  Non-silent mutations/tumor       72.66          81.24                                          64.71           0.895   23.13    29.67    16.22    0.015       8.796E-07
  Genes mutated in \> 3% samples   785            703                                            617             0.062   213      273      97       6.339E-10   9.052E-21

S, smoker; NS, non-smoker.

The smoking status of two CR patients was unknown.

[^1]: These authors contributed equally to this work.
